The advent of targeted therapy has revolutionized the field of oncology, offering a more personalized approach to cancer treatment. Unlike conventional chemotherapy, which indiscriminately targets rapidly dividing cells, targeted therapies aim to interfere with specific molecules necessary for tumor growth and progression.
Targeted therapies can be broadly classified into two categories: small molecules and monoclonal antibodies. Small molecules are low-weight compounds that can penetrate the cell membrane and interact with intracellular targets. Monoclonal antibodies, on the other hand, are large proteins that cannot cross the cell membrane and are designed to target extracellular or cell surface molecules.
Targeted therapies work by blocking the growth signals of cancer cells, interfering with angiogenesis, promoting apoptosis, or enhancing the immune response against cancer cells. They have the advantage of being more selective, hence causing fewer side effects than traditional chemotherapy.
Despite the promising results of targeted therapies, challenges remain. These include the development of resistance, the high cost of these therapies, and the difficulty in identifying appropriate molecular targets. However, ongoing research and technological advancements promise to overcome these obstacles and broaden the application of targeted therapies in cancer treatment.
Targeted therapy represents a significant advancement in modern oncology, offering a more tailored approach to cancer treatment. By specifically targeting cancer cells, these therapies minimize damage to healthy cells and reduce side effects. Despite existing challenges, the potential of targeted therapies is vast and continues to be explored in ongoing research. As healthcare professionals, staying abreast of these developments is crucial to provide the best care for our patients.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation